PMID- 35586740
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20220711
IS  - 2211-8179 (Electronic)
IS  - 2211-8160 (Print)
IS  - 2211-8160 (Linking)
VI  - 17
IP  - 1
DP  - 2022
TI  - Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST 
      Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary 
      Intervention.
PG  - 23
LID - 10.5334/gh.1111 [doi]
LID - 23
AB  - BACKGROUND: Stress hyperglycemia is a common finding during acute myocardial 
      infarction and associated with poor prognosis. To reduce the occurrence of 
      no-reflow, prognostic factors must be identified before primary percutaneous 
      coronary intervention (PPCI). Our objective was to investigate the impact of 
      stress hyperglycemia in non-diabetic and diabetic patients on no-reflow 
      phenomenon after PPCI. METHODS: The study comprised 480 patients with ST 
      elevation myocardial infarction (STEMI) who were managed by PPCI. Patients were 
      classified into two groups according to thrombolysis in myocardial infarction 
      (TIMI) flow grade: Group I (Patients with normal flow, TIMI 3 flow) and Group II 
      (Patients with no-reflow, TIMI 0-2 flow). Patients were analyzed for clinical 
      outcomes including mortality and major adverse cardiac events. RESULTS: Incidence 
      of stress hyperglycemia was 14.8% in non-diabetic patients and 22.2% in diabetic 
      patients; the incidence of no-reflow phenomenon was 13.5% and no-reflow was 
      significantly higher in patients with stress hyperglycemia. Multivariate 
      regression analysis identified the independent predictors of no-reflow 
      phenomenon: stress hyperglycemia OR 3.247 (CI95% 1.656-6.368, P = 0.001), Killip 
      class >1 OR 1.893 (CI95% 1.004-3.570, P = 0.049) and cardiogenic shock OR 3.778 
      (CI95% 1.458-9.790, P = 0.006). CONCLUSION: Stress hyperglycemia was associated 
      with higher incidence of no-reflow phenomenon. The independent predictors of 
      no-reflow were stress hyperglycemia, Killip class >1 and cardiogenic shock.
CI  - Copyright: (c) 2022 The Author(s).
FAU - Khalfallah, Mohamed
AU  - Khalfallah M
AUID- ORCID: 0000-0002-6105-9300
AD  - Cardiovascular department, Tanta University, EG.
FAU - Maria, Dina A
AU  - Maria DA
AUID- ORCID: 0000-0002-5838-7549
AD  - Cardiovascular department, Tanta University, EG.
FAU - Allaithy, Amany
AU  - Allaithy A
AUID- ORCID: 0000-0002-2739-4914
AD  - Cardiovascular department, Tanta University, EG.
LA  - eng
PT  - Journal Article
DEP - 20220329
PL  - England
TA  - Glob Heart
JT  - Global heart
JID - 101584391
SB  - IM
MH  - Coronary Angiography/adverse effects
MH  - *Diabetes Mellitus/epidemiology
MH  - Humans
MH  - *Hyperglycemia/epidemiology
MH  - *No-Reflow Phenomenon/complications/etiology
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - *ST Elevation Myocardial Infarction/epidemiology/surgery
MH  - Shock, Cardiogenic/complications
PMC - PMC8973831
OTO - NOTNLM
OT  - Impact
OT  - ST elevation myocardial infarction
OT  - no-reflow phenomenon
OT  - primary percutaneous coronary intervention
OT  - stress hyperglycemia
COIS- The authors have no competing interests to declare.
EDAT- 2022/05/20 06:00
MHDA- 2022/05/21 06:00
PMCR- 2022/03/29
CRDT- 2022/05/19 02:30
PHST- 2021/10/19 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/05/19 02:30 [entrez]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
PHST- 2022/03/29 00:00 [pmc-release]
AID - 10.5334/gh.1111 [doi]
PST - epublish
SO  - Glob Heart. 2022 Mar 29;17(1):23. doi: 10.5334/gh.1111. eCollection 2022.